Pradyumna Agasthi

Pradyumna Agasthi

Auto-generated profile, based on publicly available information

Pradyumna Agasthi

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Lancet
Verified
Journal Article
Open access
RLRafael Lozano
Rafael Lozano
NFNancy Fullman
Nancy Fullman
JMJohn Everett Mumford
John Everett Mumford
MKMegan Knight
Megan Knight
CBCeline M Barthelemy
Celine M Barthelemy
CMChristopher J L Murray
Christopher J L Murray
Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0-100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target-1 billion more people benefiting from UHC by 2023-we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2-47·5) in 1990 to 60·3 (58·7-61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9-3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010-2019 relative to 1990-2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6-421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0-3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5-1040·3]) residing in south Asia. The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people-the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close-or how far-all populations are in benefiting from UHC. Bill & Melinda Gates Foundation.

26 May 2020 in World Journal of Cardiology
Verified
Journal Article
Open access
PAPradyumna Agasthi
Pradyumna Agasthi
SPSai Harika Pujari
Sai Harika Pujari
ATAndrew Tseng
Andrew Tseng
JGJoseph N Graziano
Joseph N Graziano
FMFrancois Marcotte
Francois Marcotte
RAReza Arsanjani
Reza Arsanjani
Management of adults with coarctation of aorta

1 March 2021 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
PAPradyumna Agasthi
Pradyumna Agasthi
HAHasan Ashraf
Hasan Ashraf
SPSai Harika Pujari
Sai Harika Pujari
MGMarlene E. Girardo
Marlene E. Girardo
ATAndrew Tseng
Andrew Tseng
RAReza Arsanjani
Reza Arsanjani

9 August 2016 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
DADemilade Adedinsewo
Demilade Adedinsewo
NTNchang Taka
Nchang Taka
PAPradyumna Agasthi
Pradyumna Agasthi
RSRajesh Sachdeva
Rajesh Sachdeva
GRGeorge Rust
George Rust
AOAnekwe Onwuanyi
Anekwe Onwuanyi
The 2013 American College of Cardiology/American Heart Association guidelines recommend statins for adults age ≤75 years who have clinical atherosclerotic cardiovascular disease (IA) and adults age 40 to 75 years with diabetes mellitus and LDL‐C 70–189 mg/dl (IA). Our aim was to estimate the prevalence and likelihood of statin use among selected statin benefit groups. Using data from the National Health and Nutrition Examination Survey (NHANES) 2011–2012, we examined 5319 adults age ≥20 years. We estimated weighted frequencies and prevalence of statin use for adults with diabetes mellitus and dyslipidemia (or low‐density lipoprotein cholesterol ≥70 mg/dL), defined as statin benefit group 1 (SBG1); and for adults with atherosclerotic cardiovascular disease, defined as statin benefit group 2 (SBG2). We constructed a logistic regression model to estimate odds of statin use in SBG1. Overall, an estimated 38.6 million Americans are on a statin. In adjusted models, uninsured and Hispanic adults were less likely to be on a statin compared with white adults; 59.5% (95% confidence interval [CI]: 53.0‐66.1) of all adults in SBG1, 58.8% (95% CI: 51.5‐66.1) of adults age 40 to 75 in SBG1, and 63.5% (95% CI: 55.6‐71.4) of all adults in SBG2 were on a statin. Although the prevalence of statin use has increased over time, Hispanic ethnicity and lack of insurance remain barriers to statin use. Black‐white racial disparities were not significant. Our study provides a baseline estimate of statin use in the noninstitutionalized population just prior to introduction of the new guidelines and provides a reference for evaluating the impact of the new guidelines on statin utilization.

1 November 2018 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
CPChristine Parsons
Christine Parsons
PAPradyumna Agasthi
Pradyumna Agasthi
FMFarouk Mookadam
Farouk Mookadam
RAReza Arsanjani
Reza Arsanjani

7 May 2020 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
PAPradyumna Agasthi
Pradyumna Agasthi
MBMatthew R. Buras
Matthew R. Buras
SSSean D. Smith
Sean D. Smith
MGMichael Golafshar
Michael Golafshar
FMFarouk Mookadam
Farouk Mookadam
RAReza Arsanjani
Reza Arsanjani